Мультиморбидность и плейотропные эффекты базисных препаратов, применяемых для лечения остеоартрита
https://doi.org/10.47360/1995-4484-2025-331-337
Аннотация
Данный обзор систематизирует современные данные о взаимосвязи остеоартрита (ОА) и коморбидных состояний, демонстрируя их взаимное негативное влияние. Особое внимание уделено базисным препаратам, в частности кристаллическому глюкозамину – сульфату, который обладает позитивными плейотропными эффектами и оказывает влияние не только на ОА, но и на сопутствующие заболевания. Продемонстрирован его потенциал в улучшении кардиометаболического статуса, микробиоты кишечника; снижении рисков нарушений углеводного обмена, подагры, деменции и смертности.
Об авторах
Л. И. АлексееваРоссия
Алексеева Людмила Ивановна
115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1
Конфликт интересов:
нет
Т. А. Раскина
Россия
650056, Кемерово, ул. Ворошилова, 22а
Конфликт интересов:
нет
Е. А. Таскина
Россия
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
нет
А. М. Лила
Россия
115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1
Конфликт интересов:
нет
Е. Л. Насонов
Россия
115522, Москва, Каширское шоссе, 34а
Конфликт интересов:
нет
Список литературы
1. Hunter DJ, March L, Chew M. Osteoarthritis in 2020 and beyond: A Lancet Commission. Lancet. 2020;396(10264):1711-1712. doi: 10.1016/S0140-6736(20)32230-3
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990– 2019: A systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222. doi: 10.1016/S01406736(20)30925-9
3. Алексеева ЛИ, Таскина ЕА, Кашеварова НГ. Остеоартрит: эпидемиология, классификация, факторы риска и прогрессирования, клиника, диагностика, лечение. Современная ревматология. 2019;13(2):9-21. doi: 10.14412/1996-7012-2019-2-9-21
4. Галушко ЕА, Большакова ТЮ, Виноградова ИБ, Иванова ОН, Лесняк ОМ, Меньшикова ЛВ, и др. Структура ревматических заболеваний среди взрослого населения России по данным эпидемиологического исследования (предварительные результаты). Научно-практическая ревматология. 2009;47(1):11-17. doi: 10.14412/1995-4484-2009-136
5. Kovari E, Kaposi A, Bekes G, Kiss Z, Kurucz R, Mandl P, et al. Comorbidity clusters in generalized osteoarthritis among female patients: A cross-sectional study. Semin Arthritis Rheum. 2020;50(2):183-191. doi: 10.1016/j.semarthrit.2019.09.001
6. Swain S, Sarmanova A, Coupland C, Doherty M, Zhang W. Comorbidities in Osteoarthritis: A systematic review and meta-analysis of observational studies. Arthritis Care Res. 2020;72(7):991-1000. doi: 10.1002/acr.24008
7. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: A systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4
8. Leyland KM, Gates LS, Sanchez-Santos MT, Nevitt MC, Felson D, Jones G, et al.; PCCOA Steering Committee. Knee osteoarthritis and time-to all-cause mortality in six community-based cohorts: An international meta-analysis of individual participantlevel data. Aging Clin Exp Res. 2021;33(3):529-545. doi: 10.1007/s40520-020-01762-2
9. Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: Population based cohort study. BMJ. 2011;342:d1165. doi: 10.1136/bmj.d1165
10. Wang H, Bai J, He B, Hu X, Liu D. Osteoarthritis and the risk of cardiovascular disease: A meta-analysis of observational studies. Sci Rep. 2016;6:39672. doi: 10.1038/srep39672
11. Rahman MM, Kopec JA, Cibere J, Goldsmith CH, Anis AH. The relationship between osteoarthritis and cardiovascular disease in a population health survey: A cross-sectional study. BMJ Open. 2013;3(5):e002624. doi: 10.1136/bmjopen-2013-002624
12. Mathieu S, Couderc M, Tournadre A, Soubrier M. Cardiovascular profile in osteoarthritis: A meta-analysis of cardiovascular events and risk factors. Joint Bone Spine. 2019;86(6):679-684. doi: 10.1016/j.jbspin.2019.06.013
13. Macêdo MB, Santos VMOS, Pereira RMR, Fuller R. Association between osteoarthritis and atherosclerosis: A systematic review and meta-analysis. Exp Gerontol. 2022;161:111734. doi: 10.1016/j.exger.2022.111734
14. Xie Y, Zhou W, Zhong Z, Zhao Z, Yu H, Huang Y, et al. Metabolic syndrome, hypertension, and hyperglycemia were positively associated with knee osteoarthritis, while dyslipidemia showed no association with knee osteoarthritis. Clin Rheumatol. 2021;40(2):711-724. doi: 10.1007/s10067-020-05216-y
15. King KB, Rosenthal AK. The adverse effects of diabetes on osteoarthritis: Update on clinical evidence and molecular mechanisms. Osteoarthritis Cartilage. 2015;23(6):841-850. doi: 10.1016/j.joca.2015.03.031
16. Louati K, Vidal C, Berenbaum F, Sellam J. Association between diabetes mellitus and osteoarthritis: Systematic literature review and meta-analysis. RMD Open. 2015;1(1):e000077. doi: 10.1136/rmdopen-2015-000077
17. Schwab P, Dhamane AD, Hopson SD, Moretz C, Annavarapu S, Burslem K, et al. Impact of comorbid conditions in COPD patients on health care resource utilization and costs in a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis. 2017;12:735-744. doi: 10.2147/COPD.S112256
18. Huang SW, Wang WT, Chou LC, Liao CD, Liou TH, Lin HW. Osteoarthritis increases the risk of dementia: A nationwide cohort study in Taiwan. Sci Rep. 2015;5:10145. doi: 10.1038/srep10145
19. Ryu E, Chamberlain AM, Pendegraft RS, Petterson TM, Bobo WV, Pathak J. Quantifying the impact of chronic conditions on a diagnosis of major depressive disorder in adults: A cohort study using linked electronic medical records. BMC Psychiatry. 2016;16:114. doi: 10.1186/s12888-016-0821-x
20. Lazar V, Ditu LM, Pircalabioru GG, Gheorghe I, Curutiu C, Holban AM, et al. Aspects of gut microbiota and immune system interactions in infectious diseases, immunopathology, and cancer. Front Immunol. 2018;9:1830. doi: 10.3389/fimmu.2018.01830
21. Favazzo LJ, Hendesi H, Villani DA, Soniwala S, Dar QA, Schott EM, et al. The gut microbiome-joint connection: Implications in osteoarthritis. Curr Opin Rheumatol. 2020;32(1):92-101. doi: 10.1097/BOR.0000000000000681
22. Schott EM, Farnsworth CW, Grier A, Lillis JA, Soniwala S, Dadourian GH, et al. Targeting the gut microbiome to treat the osteoarthritis of obesity. JCI Insight. 2018;3(8):e95997. doi: 10.1172/jci.insight.95997
23. Griffin TM, Huebner JL, Kraus VB, Yan Z, Guilak F. Induction of osteoarthritis and metabolic inflammation by a very high-fat diet in mice: Effects of short-term exercise. Arthritis Rheum. 2012;64(2):443-453. doi: 10.1002/art.33332
24. Yusuf E, Nelissen RG, Ioan-Facsinay A, Stojanovic-Susulic V, DeGroot J, van Osch G, et al. Association between weight or body mass index and hand osteoarthritis: A systematic review. Ann Rheum Dis. 2010;69(4):761-765. doi: 10.1136/ard.2008.106930
25. Boer CG, Radjabzadeh D, Uitterlinden AG, Kraaij R, van Meurs JB. The role of the gut microbiome in osteoarthritis and joint pain. Osteoarthr. Cartil. 2017;25:S10. doi: 10.1016/j.joca.2017.02.033
26. Coulson S, Butt H, Vecchio P, Gramotnev H, Vitetta L. Greenlipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: Therapeutic efficacy and effects on gastrointestinal microbiota profiles. Inflammopharmacology. 2013;21(1):79-90. doi: 10.1007/s10787-012-0146-4
27. Wang X, Hunter D, Xu J, Ding C. Metabolic triggered inflammation in osteoarthritis. Osteoarthritis Cartilage. 2015;23(1):22-30. doi: 10.1016/j.joca.2014.10.002
28. Liu Y, Ding W, Wang HL, Dai LL, Zong WH, Wang YZ, et al. Gut microbiota and obesity-associated osteoarthritis. Osteoarthritis Cartilage. 2019;27(9):1257-1265. doi: 10.1016/j.joca.2019.05.009
29. Wang J, Gu X, Yang J, Wei Y, Zhao Y. Gut microbiota dysbiosis and increased plasma LPS and TMAO levels in patients with preeclampsia. Front Cell Infect Microbiol. 2019;9:409. doi: 10.3389/fcimb.2019.00409
30. Hao X, Shang X, Liu J, Chi R, Zhang J, Xu T. The gut microbiota in osteoarthritis: Where do we stand and what can we do? Arthritis Res Ther. 2021;23(1):42. doi: 10.1186/s13075-021-02427-9
31. Boutagy NE, McMillan RP, Frisard MI, Hulver MW. Metabolic endotoxemia with obesity: Is it real and is it relevant? Biochimie. 2016;124:11-20. doi: 10.1016/j.biochi.2015.06.020
32. Berenbaum F. Deep phenotyping of osteoarthritis: A step forward. Ann Rheum Dis. 2019;78(1):3-5. doi: 10.1136/annrheumdis-2018-213864
33. Chadha R. Revealed aspect of metabolic osteoarthritis. J Orthop. 2016;13(4):347-351. doi: 10.1016/j.jor.2016.06.029
34. Sellam J, Berenbaum F. Is osteoarthritis a metabolic disease? Joint Bone Spine. 2013;80(6):568-573. doi: 10.1016/j.jbspin.2013.09.007
35. Berenbaum F, Griffin TM, Liu-Bryan R. Review: Metabolic regulation of inflammation in osteoarthritis. Arthritis Rheumatol. 2017;69(1):9-21. doi: 10.1002/art.39842
36. Turroni S, Pedersini P, Villafañe JH. The human gut microbiome and its relationship with osteoarthritis pain. Pain Med. 2021;22(7):1467-1469. doi: 10.1093/pm/pnaa422
37. Алексеева ЛИ, Лила АМ. Базисная терапия остеоартрита: современный взгляд на применение препаратов глюкозамина и хондроитина. Современная ревматология. 2021;15(2):112119. doi: 10.14412/1996-7012-2021-2-112-119
38. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005(2):CD002946. doi: 10.1002/14651858.CD002946.pub2
39. Eriksen P, Bartels EM, Altman RD, Bliddal H, Juhl C, Christensen R. Risk of bias and brand explain the observed inconsistency in trials on glucosamine for symptomatic relief of osteoarthritis: A meta-analysis of placebo-controlled trials. Arthritis Care Res (Hoboken). 2014;66(12):1844-1855. doi: 10.1002/acr.22376
40. Gregori D, Giacovelli G, Minto C, Barbetta B, Gualtieri F, Azzolina D, et al. Association of pharmacological treatments with longterm pain control in patients with knee osteoarthritis: A systematic review and meta-analysis. JAMA. 2018;320(24):2564-2579. doi: 10.1001/jama.2018.19319
41. Beaudart C, Lengelé L, Leclercq V, Geerinck A, Sanchez-Rodriguez D, Bruyère O, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: A systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80(18):1947-1959. doi: 10.1007/s40265-020-01423-8
42. Филатова ЮС, Яльцева НВ, Леонтьева ЕА. Плейотропные эффекты терапии остеоартрита. Медицинский совет. 2024;18(22):96-104. doi: 10.21518/ms2024-53
43. Sibbritt D, Adams J, Lui CW, Broom A, Wardle J. Who uses glucosamine and why? A study of 266,848 Australians aged 45 years and older. PLoS One. 2012;7:e41540. doi: 10.1371/journal.pone.0041540
44. Bell GA, Kantor ED, Lampe JW, Shen DD, White E. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012;27:593-603. doi: 10.1007/s10654-012-9714-6
45. Weimer S, Priebs J, Kuhlow D, Groth M, Priebe S, Mansfeld J, et al. D-glucosamine supplementation extends life span of nematodes and of ageing mice. Nat Commun. 2014;5:3563. doi: 10.1038/ncomms4563
46. Bazzano LA, Hu T, Reynolds K, Yao L, Bunol C, Liu Y, et al. Effects of low-carbohydrate and low-fat diets: A randomized trial. Ann Intern Med. 2014;161(5):309-318. doi: 10.7326/M14-0180
47. Yao D, Xu L, Xu O, Li R, Chen M, Shen H, et al. O-linked β-N acetylglucosamine modification of A20 enhances the inhibition of NF-κB (nuclear factor-κB) activation and elicits vascular protection after acute endoluminal arterial injury. Arterioscler Thromb Vasc Biol. 2018;38(6):1309-1320. doi: 10.1161/ATVBAHA.117.310468
48. Ma H, Li X, Sun D, Zhou T, Ley SH, Gustat J, et al. Association of habitual glucosamine use with risk of cardiovascular disease: Prospective study in UK Biobank. BMJ. 2019;365:l1628. doi: 10.1136/bmj.l1628
49. Patti ME, Virkamäki A, Landaker EJ, Kahn CR, Yki-Järvinen H. Activation of the hexosamine pathway by glucosamine in vivo induces insulin resistance of early postreceptor insulin signaling events in skeletal muscle. Diabetes. 1999;48(8):1562-1571. doi: 10.2337/diabetes.48.8.1562
50. Yomogida S, Hua J, Sakamoto K, Nagaoka I. Glucosamine suppresses interleukin-8 production and ICAM-1 expression by TNF-alpha-stimulated human colonic epithelial HT-29 cells. Int J Mol Med. 2008;22(2):205-211.
51. Azuma K, Osaki T, Wakuda T, Tsuka T, Imagawa T, Okamoto Y, et al. Suppressive effects of N-acetyl-D-glucosamine on rheumatoid arthritis mouse models. Inflammation. 2012;35(4):1462-1465. doi: 10.1007/s10753-012-9459-0
52. Hu FB, Stampfer MJ. Is type 2 diabetes mellitus a vascular condition? Arterioscler Thromb Vasc Biol. 2003;23(10):1715-1716. doi: 10.1161/01.ATV.0000094360.38911.71
53. Ma H, Li X, Zhou T, Sun D, Liang Z, Li Y, et al. Glucosamine use, inflammation, and genetic susceptibility, and incidence of type 2 diabetes: A prospective study in UK biobank. Diabetes Care. 2020;43(4):719-725. doi: 10.2337/dc19-1836
54. Liu M, Ye Z, Zhang Y, Yang S, Wu Q, Zhou C, et al. Associations of habitual glucosamine supplementation with incident gout: A large population based cohort study. Biol Sex Differ. 2022;13(1):52. doi: 10.1186/s13293-022-00461-z
55. Li G, Zhang X, Liu Y, Zhang J, Li L, Huang X, et al. Relationship between glucosamine use and the risk of lung cancer: Data from a nationwide prospective cohort study. Eur Respir J. 2022;59(3):2101399. doi: 10.1183/13993003.01399-2021
56. Zheng J, Ni C, Zhang Y, Huang J, Hukportie DN, Liang B, et al. Association of regular glucosamine use with incident dementia: Evidence from a longitudinal cohort and Mendelian randomization study. BMC Med. 2023;21(1):114. doi: 10.1186/s12916-023-02816-8
57. Li ZH, Gao X, Chung VC, Zhong WF, Fu Q, Lv YB, et al. Associations of regular glucosamine use with all-cause and cause-specific mortality: A large prospective cohort study. Ann Rheum Dis. 2020;79(6):829-836. doi: 10.1136/annrheumdis-2020-217176
Рецензия
Для цитирования:
Алексеева Л.И., Раскина Т.А., Таскина Е.А., Лила А.М., Насонов Е.Л. Мультиморбидность и плейотропные эффекты базисных препаратов, применяемых для лечения остеоартрита. Научно-практическая ревматология. 2025;63(4):331-337. https://doi.org/10.47360/1995-4484-2025-331-337
For citation:
Alekseeva L.I., Raskina T.A., Taskina E.A., Lila A.M., Nasonov E.L. Multimorbidity and pleiotropic effects of basic drugs used for the treatment of osteoarthritis. Rheumatology Science and Practice. 2025;63(4):331-337. (In Russ.) https://doi.org/10.47360/1995-4484-2025-331-337